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trict regulation of DNA replication is essential to
ensure  proper duplication and segregation of chro-
mosomes during the cell cycle, as its deregulation can
lead to genomic instability and cancer. Thus, eukaryotic
organisms have evolved multiple mechanisms to restrict
DNA replication to once per cell cycle. Here, we show that
inactivation of Geminin, an inhibitor of origin licensing,
leads to rereplication in human normal and tumor cells
within the same cell cycle. We found a CHK1-dependent
S
 
checkpoint to be activated in rereplicating cells accompanied
by formation of 
 
 
 
H2AX and RAD51 nuclear foci. Abrogation
of the checkpoint leads to abortive mitosis and death of
rereplicated cells. In addition, we demonstrate that the
induction of rereplication is dependent on the replication
initiation factors CDT1 and CDC6, and independent of the
functional status of p53. These data show that Geminin is
required for maintaining genomic stability in human cells.
 
Introduction
 
Licensing of DNA replication origins occurs by the assem-
bly of a prereplicative complex of initiation proteins during
late mitosis and early G1. Phosphorylation, nuclear exclusion,
and degradation of initiation proteins have been described
as important mechanisms preventing rereplication of origins
during the same cell cycle (Kelly and Brown, 2000; Bell and
Dutta, 2002). In common for several of these mechanisms
is that they are regulated by Cdks, and in fact, the inacti-
vation of the B-type cyclins in yeast is sufficient for the
induction of rereplication (Kelly and Brown, 2000; Bell
and Dutta, 2002). An additional level of control has
evolved in higher eukaryotes and is presented by Geminin.
Geminin was originally discovered in 
 
Xenopus
 
 as a protein
degraded by the anaphase-promoting complex at the end
of mitosis (McGarry and Kirschner, 1998). Geminin ortho-
logues were subsequently found in other higher eukaryotes,
including 
 
Drosophila
 
, mouse, and human, and it was found
to inhibit the activity of CDT1 (Wohlschlegel et al., 2000;
Quinn et al., 2001; Tada et al., 2001). Geminin has been
shown to be a main inhibitor of origin licensing in mitotic
 
Xenopus
 
 extracts; however, depletion of Geminin in 
 
Xenopus
 
is not sufficient for induction of rereplication (McGarry
and Kirschner, 1998; Tada et al., 2001; McGarry, 2002).
In contrast, Geminin deficiency in 
 
Drosophila
 
 leads to
partial overreplication of the genome (Quinn et al., 2001;
Mihaylov et al., 2002). Although these data demonstrate
that Geminin is an important regulator of origin licensing
in both organisms, they also suggest that some organisms
have evolved additional levels of checkpoint controls to
prevent rereplication in addition to Geminin. Consistent
with this suggestion is recent results, obtained in human
cell lines, in which inactivation of p53 was required for
inducing rereplication as a consequence of CDT1 and
CDC6 overexpression (Vaziri et al., 2003). Here, we have
addressed the functional role of Geminin in human cells
by inhibiting its expression using small interfering RNA
(siRNA). We show that inhibition of Geminin expression
is sufficient to induce rereplication in the presence of
functional p53. These results demonstrate that Geminin is
essential in human cells to prevent rereplication, and loss of
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Geminin is sufficient to induce genomic stability. Because
genomic stability has been suggested to be one of the key
features of human cancer, our results suggest that Geminin
is a putative tumor suppressor gene.
 
Results
 
Geminin is essential for preventing rereplication 
in human cells
 
To examine the role of Geminin in mammalian cells, we
abolished its expression in HCT116 colon carcinoma cells
using siRNA. Treatment of the cells with Geminin siRNA
(but not control) led to a rapid drop of Geminin protein lev-
els (Fig. 1 A). After 48 h of siRNA, most Geminin-depleted
cells were enlarged and contained a single giant nucleus (Fig.
1 B). FACS
 
®
 
 analysis showed a significant proportion of
Geminin-depleted cells with 4N and greater DNA content
(Fig. 1 C). These cells incorporated BrdU during a 2-h pulse
period and expressed high levels of cyclin B1 (Fig. 1 C).
These data suggest that Geminin-depleted cells accumulate
in S phase with rereplicated DNA. Similar results were ob-
tained in U2OS osteosarcoma cells and TIG3 human dip-
loid fibroblasts (see Figs. 2, 3, and 5).
To examine if rereplication occurs during a single cell
cycle, we separated BrdU-labeled DNA according to mass
by CsCl density ultracentrifugation. This method allows
the separation of DNA labeled with BrdU on both strands
(rereplicated; heavy-heavy), on one strand (replicated only
once; heavy-light), and on no strands (unreplicated DNA,
light-light; Blow and Laskey, 1988; Yamaguchi and Dutta,
2000). We developed a protocol in which Geminin expres-
sion was inhibited after exit of mitosis (Fig. 1, D and E).
Cells were released from mitosis, transfected with Geminin
siRNA, and labeled with BrdU for a single cell cycle (24 h).
DNA was isolated and separated by CsCl density cen-
trifugation. Analysis of CsCl gradient fractions from Gem-
inin-depleted cells revealed three separate peaks of DNA
corresponding to rereplicated (heavy-heavy), replicated
(heavy-light), and unreplicated (light-light) DNA, whereas
control cells did not contain rereplicated DNA (Fig. 1 F).
The authenticity of the heavy-heavy fraction was shown in
control experiments in which cells were labeled for two
consecutive cycles with BrdU (unpublished data). Further-
more, we performed parallel analysis to measure BrdU
incorporation and mitotic histone H3 phosphorylation
throughout the 48-h time course. The results from these
Figure 1. Depletion of Geminin by 
siRNA induces rereplication. Western 
blot (A) and phase-contrast microscopic 
images (B) of HCT116 cells treated with 
Geminin or control (GL2) siRNA for 48 h. 
Western blots were probed with anti-
bodies specific for Geminin and Vinculin 
(loading control). (C) Flow cytometric 
profiles of HCT116 treated with Geminin 
siRNA for 48 h. Before harvesting, the 
cells were pulsed with BrdU for 2 h and 
processed for combined propidium iodide 
staining together with cyclin B1– and 
BrdU-specific antibodies. The black bars 
in the phase-contrast pictures correspond 
to 10  m. (D) Summary of the protocol 
used in Geminin siRNA–treated U2OS 
cells to measure DNA rereplication 
within a single cell cycle. (E) Geminin 
expression levels in U2OS cells released 
from nocodazole block and treated with 
GL2 (control) or Geminin siRNA. (F) 
Distribution of [
3H]thymidine-labeled 
DNA in the CsCl gradient fractions. U2OS 
cells were processed according to the 
protocol described in A. DNA was pre-
pared and subjected to CsCl density 
gradient centrifugation as described in 
Materials and methods. Y axes: [
3H]thy-
midine radioactivity in cpm; x axes: 
number of gradient fraction collected 
from the bottom. The fractions containing 
LL (light-light), HL (heavy-light), and HH 
(heavy-heavy) DNA were determined 
by a series of control experiments (not 
depicted). 
Loss of Geminin induces rereplication |
 
 Melixetian et al. 475
 
experiments showed that rereplication occurs in Geminin-
depleted cells within one single S phase without interven-
ing mitosis (see Fig. 5).
As a control for the specificity of the siRNA oligonucle-
otides, we reconstituted Geminin expression by creating
two different U2OS cells lines expressing HA-tagged Gem-
inin in which two residues in the siRNA target sequence
were changed in a way that the nucleotide sequence, but
not the amino acid, was altered (Fig. 2). Treatment of
these cell lines with siRNA to Geminin led to specific de-
crease of endogenous Geminin levels, and a strong reduc-
tion in the number of cells with 4N and greater DNA content
(Fig. 2), demonstrating that rereplication is a consequence
of Geminin loss.
 
Geminin depletion leads to rereplication in normal 
diploid human cells
 
Next, we wished to investigate on a single-cell basis
whether rereplicated DNA originated from early- or late-
firing replication origins. To examine this, we performed
FISH using as probes bacterial artificial chromosome
(BAC) clones containing the chromosomal regions of ei-
ther the lamin B2 (early firing) or the 
 
 
 
-globin (late firing)
replication origins (Kitsberg et al., 1993; Abdurashidova et
al., 2000; Avni et al., 2003). The specific hybridization of
the BAC clones to their relevant chromosomal loci was
Figure 2. Rescue of Geminin siRNA phenotype in cells stably 
expressing HA-tagged RNAi mutants of Geminin. U2OS cell lines 
expressing two different mutant HA-tagged versions of Geminin 
were generated (Geminin- i179 and Geminin- i179-2). In the 
cDNA for Geminin, two residues were changed in the siRNA target 
sequence in a way that the nucleotide sequence, but not the amino 
acid sequence, was altered (C). The cell lines were treated with 
Geminin siRNA for 48 h and analyzed by Western blot with anti-
bodies specific for the indicated proteins (A) and by FACS
® analysis 
for DNA content (B). Note the decrease in cells with DNA content 
greater than and equal to 4N.
Figure 3. Loss of Geminin leads to rereplication of DNA both from early- and late-firing origins. (A) Representative FISH experiment 
performed on HCT116 colon carcinoma cells and TIG3 human diploid fibroblasts. HCT116 cells were treated with siRNA for 48 h, and TIG3 
cells for 96 h. BAC probes corresponding to lamin B2 and  -globin replication origin containing chromosome segments were labeled with 
Cy3-dUTP (red) and used for hybridization. Chromosomal DNA was stained with DAPI. The BAC clones hybridize exclusively with relevant 
single chromosomal loci at 19p13.3 (lamin B2) and 11p15.4 ( -globin) (not depicted). (B) Histograms summarizing results obtained from 
examination of at least 200 nuclei of each culture, hybridized with the indicated FISH probe. For statistically significant FISH phenotypes 
(Geminin vs. GL2 siRNA), P values calculated from a two-tailed test are indicated. Bar, 3  m. 
476 The Journal of Cell Biology 
 
|
 
 
 
Volume 165, Number 4, 2004
 
confirmed in separate experiments (unpublished data).
HCT116 colon carcinoma cells and TIG3 human diploid
fibroblasts were treated with Geminin or control siRNA
and FISH analysis was performed. As demonstrated in Fig.
3, Geminin depletion both in HCT116 and TIG3 cells
lead to accumulation of cells containing more than four
foci for each replication origin region, demonstrating that
rereplication affects both early and late origins. Interest-
ingly, we noted that hybridization foci in both HCT116
and TIG3 cells corresponding to the rereplicated lamin B2
origin region were efficiently separated within nucleus,
whereas spots corresponding to the rereplicated 
 
 
 
-globin
region were found to be clustered in two nuclear regions,
which could correspond to each chromosome (Fig. 3 A).
These data are consistent with the fact that newly synthe-
sized DNA at heritable silenced genes and heterochromatic
domains separate poorly due to enhanced sister chromatid
cohesion (Hansen et al., 1995; Gartler et al., 1999; Azuara
et al., 2003). Based on these results, we conclude that
Geminin is required for preventing rereplication both in
transformed and primary cells.
 
Inhibition of Geminin expression activates CHK1 
and a DNA damage response
 
We found that proliferation is inhibited in Geminin-
depleted cells (unpublished data; Fig. 8), suggesting the pos-
sible activation of a checkpoint in cells undergoing rereplica-
tion. To investigate the mechanism leading to cessation of
proliferation, we analyzed if DNA damage checkpoint path-
ways were activated in Geminin-depleted cells. As shown in
Fig. 4 A, depletion of Geminin led to a dramatic increase in
phosphorylation of CHK1 on serine (S) 317, inhibitory
phosphorylation of CDC2 on tyrosine (Y) 15, and phos-
phorylation of p53 on S15. These are the hallmarks of ATR/
ATM-dependent DNA damage checkpoint activation (Bar-
tek and Lukas, 2001; Shiloh, 2003). Consistent with in-
creased p53 S15 phosphorylation, p53 levels were increased
in Geminin-depleted cells; however, the expression of p21, a
transcriptional target of p53, was induced only at later time
points (48 h), suggesting that p21 activation is a secondary
response to rereplication. To confirm that rereplication acti-
vates the DNA damage checkpoint, we analyzed if rerepli-
cating cells contained DNA damage–induced nuclear foci.
In fact, we observed H2AX and RAD51 nuclear foci forma-
tion in rereplicating cells (Fig. 4 B). H2AX phosphorylation
is an early mark of double-stranded DNA breaks (DSBs)
and is essential for a proper checkpoint response, whereas
RAD51 is involved in homologous recombination (Shiloh,
2003). These data suggest that rereplication leads to accu-
mulation of DSBs.
An important intermediate for activation of the check-
point in response to DNA damage and stalled replication
forks is single-stranded DNA (ssDNA; Zou and Elledge,
2003). Therefore, we examined if ssDNA is present in rerep-
licating cells. To do this, we measured the incorporation of
BrdU without prior DNA denaturation (Raderschall et al.,
1999). Geminin-depleted cells (but not controls) contained
numerous BrdU foci colocalizing with the ssDNA-binding
protein RPA70 (Fig. 4 C). These observations suggest that
rereplication leads to formation of DNA strand breaks. The
mechanism by which DNA strand breaks are generated is
unclear; however, one possible scenario is that unscheduled
Figure 4. Rereplication induced by 
Geminin depletion activates CHK1 and 
a DNA damage response. (A) Western 
blot analysis of cellular extracts prepared 
at the indicated time points from HCT116 
cells treated with Geminin or control 
(GL2) siRNAs. S317CHK1, Y15CDC2, 
and S15p53 indicate the use of antibodies 
specifically recognizing the phosphory-
lated amino acid of the proteins. (B) 
Rereplicated cells contain H2AX and 
Rad51 nuclear foci. U2OS cells treated 
with control (GL2) or Geminin siRNA for 
48 h were immunostained with rabbit 
polyclonal H2AX and RAD51 antibodies. 
(C) Rereplicated cells contain ssDNA 
coated by RPA70. HCT116 cells were 
prelabeled with 10  M BrdU for 24 h, 
incubated with Geminin or control (GL2) 
siRNA for 48 h, fixed with methanol, and 
immunostained with a BrdU-specific 
antibody without denaturation of DNA. 
BrdU foci (green) correspond to the sites 
of ssDNA breaks. RPA immunostaining 
is shown in red. (D) Formation of giant 
nuclei and CHK1 activation in TIG3 
human diploid fibroblasts treated with 
Geminin siRNA. TIG3 cells were trans-
fected twice with GL2 (control) or Gemi-
nin siRNA, fixed, and stained 96 h after 
the first transfection. 
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Figure 5. Geminin depletion activates the checkpoint response during S phase. U2OS cells were transfected with siRNA to Geminin or 
control and synchronized in mitosis by nocodazole treatment for 16 h. The cells were subsequently released into the next cell cycle and 
retransfected with Geminin or control siRNA. The cells were harvested at the indicated time points and analyzed by Western blot using the 
indicated antibodies (A), and for DNA content by FACS
® analysis (B). (C) Cells grown on the coverslips were labeled with BrdU for 10 min at 
each time point, pre-extracted with 0.5% Triton X-100 in cytoskeleton buffer, fixed with PFA, and immunostained for BrdU and chromatin-
bound MCM2. (D) Kinetics of DNA damage checkpoint induction and progression through mitosis of Geminin- or control siRNA–treated 
cells. The cells were plated on poly-D-lysine–coated coverslips, fixed, and stained with phosphohistone H3 and  H2AX antibodies. 70 cells 
were counted for each time point.
 
reinitiation of DNA replication could lead to replication
fork collision and the generation of single-stranded DNA
breaks, which subsequently could lead to replication fork
collapse and DSB (Kuzminov, 2001).
To investigate if inhibition of Geminin expression also re-
sults in checkpoint activation in normal human diploid fi-
broblasts, we transfected TIG3 fibroblasts with control
(GL2) or Geminin siRNA. As shown in Fig. 4 D, the inhibi-
tion of Geminin expression in TIG3 cells also leads to the
strong activation of CHK1 and the formation of giant cells.
These results are all consistent with the notion that loss of
Geminin is sufficient for the induction of rereplication in
diploid cells.
Next, we investigated at which stage of the cell cycle Gem-
inin depletion leads to checkpoint activation. We analyzed
cell cycle progression of cells synchronized in mitosis by no-
codazole treatment and released into the next cell cycle in
the presence of Geminin or control siRNA (Fig. 5 A). Gem-
inin-depleted cells progress normally into S phase (Fig. 6 B).
In contrast to control-treated cells, Geminin-depleted cells
continue to incorporate BrdU and show constant association
of MCM2 with chromatin throughout the 30-h period after
exiting mitosis (Fig. 5 C). Moreover, Geminin-depleted cells
(but not controls) appear to arrest in S phase because the mi-
totic indices of Geminin-depleted cells, as measured by
phopshohistone H3 staining, remained low throughout the
period (Fig. 5 D; see also Fig. 5 A). The checkpoint response
was activated during the first hours of S phase as monitored
by the activatory phosphorylation of CHK1 and histone
H2AX (Fig. 5, A and D). Together, our results show that in-
hibition of Geminin expression leads to rereplication within
the same cycle, checkpoint activation, and subsequent block
in entry into mitosis.
 
Abrogation of the CHK1-dependent checkpoint leads 
to abortive mitosis and death of rereplicated cells
 
To understand the functional significance of CHK1-depen-
dent checkpoint activation in response to rereplication, we
treated rereplicated cells with caffeine and UCN01. Caffeine
inhibits both ATM and ATR kinases (Sarkaria et al., 1999),
whereas UCN01 is an inhibitor of CHK1 kinase (Busby et
al., 2000). HCT116 cells treated with Geminin siRNA for
48 h were incubated with caffeine or UCN01 (Fig. 6). Al-
ready after 1 h of drug treatment, rereplicated cells started to
enter mitosis as monitored by accumulation of cells staining
positive for phosphohistone H3 (Fig. 6 A). However, the 
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treated cells did not complete mitosis, and 24 h after incuba-
tion with drugs we observed reduction in number of cells
with DNA content 
 
 
 
4N and accumulation of dead cells
(Fig. 6 B). In contrast, control cells showed only modest ac-
cumulation of mitotic cells upon 1 h of UCN01 treatment
(Fig. 6 A) and did not undergo apoptosis after 24 h of treat-
ment (Fig. 6 B). Analysis of mitotic spreads from Gemi-
nin-depleted cells treated with UCN01 revealed extensive
chromosomal breakage and, in some cells, chromosome frag-
mentation (Fig. 6 C). These data indicate that rereplicated
cells undergo “mitotic catastrophe” in the presence of check-
point inhibitors. Thus, checkpoint inhibition in rereplicat-
ing cells does not lead to further rereplication, but induces
abortive mitosis and cell death.
 
Rereplication is induced in the presence of functional p53
 
p53 plays an important role in the DNA damage response,
and it was recently reported to prevent rereplication in-
duced by CDT1 and CDC6 overexpression in human cells
(Vaziri et al., 2003). Because we observed rereplication in
human diploid fibroblasts as well as in transformed cell
lines HCT116 and U2OS that have often been used as
model cell lines for monitoring functional p53 (Heise et
al., 1997; Bunz et al., 1998), our data demonstrate that the
presence of functional p53 is not sufficient for preventing
rereplication. However, p53 could be involved in regulat-
ing the DNA damage checkpoint induced by Geminin de-
pletion. To analyze this, we used cells in which p53 expres-
sion was abolished by a retrovirus expression, a short
hairpin RNA against p53 (U2OS), or by overexpression of
human papilloma virus E6 (HCT116). Ablation of p53 ab-
rogated p21 induction in HCT116 cells, but did not pro-
mote further rereplication and did not affect CHK1 activa-
tion in both cell lines (Fig. 7). These data suggest that
inactivation of p53 is not required for the induction of re-
replication or the rereplication checkpoint. Moreover, in-
activation of p53 did not affect death of rereplicated cells
upon caffeine and UCN01 treatment (unpublished data),
consistent with the notion that p53 is not involved in cell
death as a consequence of mitotic catastrophe (Roninson et
al., 2001).
 
CDT1 and CDC6 are required for rereplicaton induced 
by Geminin deficiency
 
To investigate the mechanism by which rereplication is in-
duced by loss of Geminin expression, we abolished the ex-
Figure 6. Inhibition of CHK1-dependent checkpoint leads to abortive mitosis and death of rereplicated cells. (A) Rereplicated cells enter 
mitosis when treated with caffeine or UCN01. HCT116 cells were incubated with Geminin-specific or control (GL2) siRNA for 48 h, and 
subsequently treated with 5 mM caffeine or 300 nM UCN01 for 2 h. Entry into mitosis was measured with phosphohistone H3 staining by 
FACS
®. (B) Death of rereplicated cells upon prolonged treatment with checkpoint inhibitors. HCT116 cells were treated as described in A, but 
the incubation period with caffeine and UCN01 was prolonged to 24 h. The percentage of dead (subG1) and polyploid cells ( 4N) was 
determined by propidium iodide staining and FACS
® analysis. (C) Extensive chromosomal breakage in rereplicated cells treated with UCN01. 
The cells were treated with UCN01 as in A and then incubated in the presence of colcemid for 30 min. Metaphase spreads were prepared as 
described in the Materials and methods. Two cells with different extent of chromosome breaks are shown. We never observed any chromosome 
breaks in cells treated with UCN01, nor in cells treated with GL2 siRNA. More than 50% of the Geminin siRNA–transfected and UCN01-
treated cells showed extensive chromosomal breakage, which in this experiment were corresponding to the transfection efficiency of the 
siRNA oligonucleotide to Geminin. Insets show magnified views of chromosomes marked with white boxes. 
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pression of CDT1 and CDC6, two proteins required for the
licensing of origins. Co-silencing of CDT1 or CDC6 in
combination with Geminin prevented formation of giant
nuclei and accumulation of rereplicated cells (Fig. 8, A–C;
unpublished data), suggesting that rereplication is indeed in-
duced by relicensing of origins. In addition, we found that
co-silencing of Geminin in part rescues proliferation of
CDT1-depleted cells (Fig. 8, C and D). This finding sug-
gests that a quantitative balance between CDT1 and Gemi-
nin is essential for cell proliferation.
 
Discussion
 
In this manuscript, we demonstrate that Geminin is re-
quired for maintaining genomic stability in S phase, and
that loss of Geminin expression causes rereplication in hu-
man cells (Fig. 8 E). In addition to providing an essential
function for Geminin in regulating DNA replication in
mammalian cells, our data are the first to demonstrate a
function for Geminin in S phase. Previously published data
using 
 
Xenopus
 
 extracts have pointed to a role of Geminin in
regulating origin licensing in mitosis, but not in S phase (see
discussion in Madine and Laskey, 2001), and the specific re-
quirement of Geminin in the various phases of the cell cycle
has not been addressed in other organisms. Our finding that
rereplication induced by Geminin loss is prevented by si-
multaneous loss of CDT1 or CDC6 suggests that rereplica-
tion is induced by relicensing of already-fired origins.
We found that rereplication activates a CHK1-dependent
checkpoint that provides a classical mechanism for prevent-
ing cells with damaged or unreplicated DNA to proceed into
mitosis. In this manuscript, we have not investigated the
mechanism by which rereplication can lead to activation of
CHK1; however, it is widely believed that checkpoint pro-
teins are activated on the detection of DNA damage or de-
fects occurring during replication fork progression (Zhou
and Elledge, 2000). Importantly, in the Geminin-depleted
cells we have not detected cells with fully rereplicated DNA,
suggesting that replication forks are stalled during the process
of rereplicaton. Several potential mechanisms could explain
the presence of stalled replication forks (which could be a
consequence of the activation of CHK1), including collision
of excessive replication forks due to the refiring of origins,
imbalance of origin-firing activities such as the cyclins, or
imbalance between replicated DNA and the histone pools
(Coverley et al., 2002; Gunjan and Verreault, 2003). We ob-
served rereplication of both early- and late-replicating chro-
mosomal domains in Geminin-depleted cells. This observa-
tion distinguishes the rereplication checkpoint described here
from the previously described replication checkpoint trig-
gered by DNA synthesis inhibitors in which checkpoint acti-
vation prevents firing of late origins in response to replication
stalling at early origins (Santocanale and Diffley, 1998;
Feijoo et al., 2001). These data suggest that the CHK1-
dependent rereplication checkpoint prevents entry into mito-
sis rather than S phase progression. Abrogation of this check-
point in rereplicated cells results in entry into mitosis and
subsequent cell death, but does not promote further rerepli-
cation. Consistent with our data, previous results using 
 
Xeno-
pus
 
 embryos (McGarry, 2002) and 
 
Drosophila
 
 cells (Mihay-
lov et al., 2002) have shown that CHK1 is activated upon
depletion of Geminin. However, in contrast to the previously
published results we provide a mechanism for the activation
of CHK1 and more importantly, also in contrast to the data
obtained in 
 
Xenopus
 
 and 
 
Drosophila
 
, we show that abrogation
of the checkpoint does not impair rereplication, but results in
mitotic catastrophe. We believe that the discrepancy between
our data and those obtained in 
 
Xenopus
 
 and 
 
Drosophila
 
 most
likely are due to the experimental approach. In particular, it
has been shown that CHK1 is required for normal prolifera-
tion (Liu et al., 2000; Takai et al., 2000), and it would there-
fore be expected that siRNA to CHK1 leads to inhibition of
cell proliferation and impairment of cell growth. In agree-
ment with this, we have observed that siRNA to CHK1 in
human cells leads to accumulation of cells in G1 and appar-
ently rescues rereplication induced by Geminin depletion
(unpublished data). However, if CHK1 is inhibited after re-
replication has occurred (as shown here using the CHK1 in-
hibitor UCN01), cells undergo mitotic catastrophe. We be-
lieve that this result makes biological sense because it
provides a classical example for how a DNA damage response
(rereplication) leads to activation of a checkpoint, and that
abrogation of the checkpoint does not rescue the DNA dam-
age response, but in contrast results in cell death.
We also demonstrate that p53 is not sufficient to prevent
rereplication in Geminin-depleted cells and that ablation of
p53 does not promote further rereplication. This result ap-
pears not to be surprising because p53 primarily controls G1
checkpoint in response to DNA damage, whereas rereplica-
tion checkpoint is induced in S phase beyond G1–S transi-
tion (Zhou and Elledge, 2000; Bartek and Lukas, 2001).
Thus, the rereplication checkpoint pathway we describe is
Figure 7. Loss of p53 is not required for rereplication or DNA 
damage response. (A) U2OS cells were infected with virus generated 
by pRetroSuper (pRS) p53 producing short hairpin RNA against p53 
or with empty virus. Cells were subsequently treated with Geminin-
specific siRNA for 48 h and analyzed by Western blotting and FACS
® 
analysis. Western blots were probed with antibodies specific for the 
indicated proteins. Actinomycin D treatment (1 nM) was used as a 
positive control for p53 activation. (B) HCT116 cells infected with 
empty virus or E6-expressing virus were treated and analyzed as in A. 
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different from the p53-dependent rereplication checkpoint
observed upon overexpression of CDT1 and CDC6 re-
ported by Vaziri et al. (2003). We believe that these differ-
ences most likely are due to the different experiment condi-
tions used. In particular, the overexpression of CDT1 and
CDC6 could result in nonphysiological activation of the
p53 pathway. In contrast, we show that inhibition of Gemi-
nin expression by siRNA is specific because we can rescue
the phenotype by overexpressing mutants of Geminin in
which the target sequence for the siRNA has been mutated.
Although several reports (for review see Bartek and Lukas,
2003; Shiloh, 2003) have shown a connection between de-
fects in DNA damage checkpoint genes and predisposition to
cancer, few have connected deregulation of DNA replication
control with the development of cancer. The demonstration
that loss of Geminin can result in rereplication shows that
this gene is required for maintaining genomic stability. To-
gether with the recent finding that 
 
CDT1
 
 can function as an
oncogene in mammalian cells (Arentson et al., 2002), our
data suggest that Geminin is a putative tumor suppressor.
 
Materials and methods
 
Cell lines, siRNA, and drug treatment
 
Human U2OS osteosarcoma, HCT116 colon carcinoma cell lines, and TIG3
human diploid fibroblasts were grown in DME containing 10% FBS. siRNA
oligonucleotides (Dharmacon) were made to the following sequences
(sense-strand): Geminin, 5
 
 
 
-AACUUCCAGCCCUGGGGUUAU-3
 
 
 
 or 5
 
 
 
-
AAUGAGCUGUCCGCAGGCUUC-3
 
 
 
; CDC6, 5
 
 
 
-AAGAAUCUGCAUGU-
GUGAGAC-3
 
 
 
; CDT1, 5
 
 
 
-AACGUGGAAGUACCCGAC-3
 
 
 
; GL2, 5
 
 
 
-
CGUACGCGGAAUACUUCGA-3
 
 
 
.
Transfections were performed with 40 nM of each RNA oligonucleotide
using Oligofectamine™ (Invitrogen) according to the instructions of the
manufacturer. TIG3 cells were treated with siRNA twice within 96 h. In
checkpoint inhibition experiments, caffeine (Sigma-Aldrich) was used at a
concentration of 5 mM. UCN01 was a gift from R.J. Shultz (National Can-
cer Institute, Bethesda, MD) and was used at a concentration of 300 nM.
 
Protein expression and antibodies
 
Cells were extracted in cytoskeleton buffer containing 0.5% Triton X-100,
10 mM Pipes, pH 6.8, 100 mM NaCl, 1.5 mM MgCl
 
2
 
, 300 mM sucrose, 1
mM each of aprotinin, leupeptin, and sodium fluoride, and 2.5 mM ortho-
vanadate. Western blotting was performed according to standard proce-
dures, and proteins were detected using the following antibodies: Geminin
(FL-209, Cat. No. 13015; Santa Cruz Biotechnology, Inc.), CDC6 (DCS
181 [Petersen et al., 1999]), CDT1 (mouse mAb raised against human
CDT1), RAD51 (Cat. No. 8349; Santa Cruz Biotechnology, Inc.), and
Figure 8. Rereplication induced by 
Geminin depletion is dependent on 
CDT1 and CDC6. HCT116 cells were 
treated with control (GL2), Geminin, 
CDT1, and CDC6 siRNA at the indicated 
combinations for 48 h. Cells were 
harvested and analyzed for protein 
expression (A), DNA content (B), and 
cell proliferation (D). (C) Phase-contrast 
microscopic images taken of cells treated 
for 48 h with the siRNA for the indicated 
transcripts. Note the rescue of giant nuclei 
formation formed in Geminin siRNA–
treated cells when cotransfected with 
CDC6 or CDT1 siRNAs. (E) Model for 
the role of Geminin in controlling origin 
firing in S phase. Rereplication results in 
the activation of an ATR-CHK1–depen-
dent checkpoint that results in block of 
entry into mitosis. Even though rerepli-
cation leads to DNA strand breaks (e.g., 
phosphorylation of H2AX and formation 
of RAD51 nuclear foci) and subsequent 
p53 activation, functional p53 does not 
appear to be involved in either regulation 
of rereplication or the DNA damage 
checkpoint response. 
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RPA70 (a gift of Jerard Hurwitz, Memorial Sloan-Kettering Cancer Center,
New York, NY). Moreover, phosphospecific antibodies to S317CHK1 (Cat.
No. 2344; Cell Signaling Technology), S15p53 (Cat. No. 9284; Cell Signal-
ing Technology), Y15CDC2 (Cat. No. 9111; Cell Signaling Technology),
H2AX (Cat. No. 07-164; UBI), and H3 (Cat. No. 06570; UBI) were used.
 
FACS
 
®
 
 analysis
 
To measure BrdU incorporation, cells were incubated with 33 
 
 
 
M BrdU
(Sigma-Aldrich) for 2 h. BrdU and cyclin B1 were detected using mouse
mAbs against BrdU (Cat. No. 347580; Becton Dickinson) and cyclin B1
(Cat. No. 554176; BD Biosciences) according to previously described pro-
cedures (Faretta et al., 1997). Imunofluorescent detection of phosphory-
lated histone H3 was performed as described previously (Xu et al., 2001).
The cells were analyzed on a Becton Dickinson Flow Cytometer using
CellQuest™ software.
 
Immunofluorescence
 
To detect H2AX and RAD51 nuclear foci, cells were preextracted with cy-
toskeleton buffer containing 0.5% Triton X-100 with protease and phos-
phatase inhibitors and were then fixed with PFA. To detect ssDNA, cells
were prelabeled with 10 
 
 
 
M BrdU for 24 h, treated with siRNA in the pres-
ence 10 
 
 
 
M BrdU for 48h, and then fixed with methanol for 5 min at
 
 
 
20
 
 
 
C. Staining with BrdU antibody was performed without prior denatur-
ation of DNA. Microscopic images were acquired with a fluorescence mi-
croscope (model BX61; Olympus) equipped with a cooled CCD camera
(model C5985; Hamamatsu Corporation) or by a confocal microscope
(model 1024; Bio-Rad Laboratories) equipped with a 20-mW argon/kryp-
ton laser. The images were acquired and analyzed using Adobe Photo-
shop
 
® 
 
5.0 software.
 
FISH
 
Mitotic spreads were prepared as described previously (Specchia et al.,
1999). BAC clones were obtained from the Children’s Oakland Research
Institute (Oakland, CA). They included BAC clone number RP11-211I3
(containing the lamin B2 replication origin) and BAC clone number RP11-
645I8 (containing the 
 
 
 
-globin replication origin). The BAC clones were
directly labeled with CY3-dUTP (Amersham Biosciences) by nick transla-
tion as described previously (Specchia et al., 1999). The labeled probes
and the cell spreads were then cohybridized with HYBrite™ (Vysis) at a
melting temperature of 69
 
 
 
C for 2 min and then at 37
 
 
 
C overnight. Post-
hybridization washes were performed at 60
 
 
 
C in 0.1
 
 
 
SSC (
 
 
 
3) followed
by DAPI counterstain. FISH analysis was performed using a fluorescent mi-
croscope (DMRXA; Leica), and images were acquired and analyzed with
FISHView 2.0 software (Applied Spectral Imaging).
 
Synchronization of the cells and CsCl density
gradient ultracentrifugation
 
To measure rereplication of DNA in U2OS cells, exponentially growing
cells were incubated with 100 nCi/ml [
 
3
 
H]-methyl-thymidine (Amersham
Biosciences) for 24 h, and then treated with 100 ng/ml nocodazole (Sigma-
Aldrich) for 16 h. Nocodazole-arrested cells were collected by mitotic
shake-off and were released from mitotic block by incubating them in no-
codazole-free medium in the presence of 100 
 
 
 
M BrdU and 100 nCi/ml
[
 
3
 
H]-methyl-thymidine. 1 h after the release, cells were treated with Gemi-
nin or control siRNA oligonucleotides and incubated for 24 h. The DNA
was prepared and analyzed by CsCl density gradient ultracentrifugation as
described previously (Yamaguchi and Dutta, 2000).
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